Literature DB >> 16291734

Changes in the epidemiology of thalassemia in North America: a new minority disease.

Elliott P Vichinsky1, Eric A MacKlin, John S Waye, Fred Lorey, Nancy F Olivieri.   

Abstract

OBJECTIVE: Changing patterns of immigration to North America, along with improved treatment, have altered the clinical spectrum of thalassemia, one of the world's most common genetic diseases. The new demography of the disease, with its widely variable phenotypes, has implications for its diagnosis, counseling, and management. Characterization of the new spectrum of this ancient disease, now predominated by minority groups, is essential for optimizing survival.
METHODS: The National Institutes of Health-sponsored North American Thalassemia Clinical Research Network (TCRN) conducted a cross-sectional study of 721 patients with thalassemia syndromes. A detailed chart review was undertaken to define the relationships between ethnic origins, genotype, and phenotype. These results were compared with 3 previous surveys of similar regions. To determine if the TCRN patient epidemiology is representative of North American patients, 87 additional programs were reviewed, and hemoglobinopathy programs from the 2 largest thalassemia regions, Ontario and California, were analyzed.
RESULTS: A total of 721 patients completed analysis in the TCRN study, including 389 (54%) patients with beta-thalassemia major, 105 (15%) patients with beta-thalassemia intermedia, 95 (13%) patients with hemoglobin E-beta-thalassemia, and 132 (18%) patients with alpha-thalassemia. beta-Thalassemia predominated in Eastern North America. Hemoglobin E-beta-thalassemia and alpha-thalassemia were common on the Western continent. Genotype broadly correlated with the clinical phenotype. However, there was marked heterogeneity in clinical phenotype among patients with similar globin mutations. In beta-thalassemia disorders, coinheritance of the alpha-thalassemia trait, triplication of alpha-thalassemia genes, and heterozygosity for the dominant beta-thalassemia allele affected the clinical phenotype. In alpha-thalassemia disorders, structural mutations such as hemoglobin H-Constant Spring resulted in a severe hemoglobin H phenotype. Sixty percent of patients received regular transfusions, and 86% received regular iron-chelation therapy. Increased survival and decreasing birth rates of Mediterranean patients resulted in an aging Greek/Italian population being replaced by a young Asian/Middle Eastern population. Now, Asian patients account for >50% of the thalassemia population. Evidence of increasing survival is reflected in an advancing mean age of white patients with thalassemia major (25 years, up from 11 years in 1974). The results of the non-TCRN thalassemia survey confirm these observations and describe a young multiethnic thalassemia population distributed throughout North America. Newborn-screening results suggest that thalassemia births in North America are increasing and reflect the change in genotype and phenotype observed in the TCRN populations.
CONCLUSIONS: The epidemiology of thalassemia in North America reflects a heterogeneous group of diseases with new ethnicities, genotypes, and phenotypes. In these communities, physicians will need to provide education, prenatal diagnosis, counseling, and management of this newly diverse group of patients.

Entities:  

Mesh:

Year:  2005        PMID: 16291734     DOI: 10.1542/peds.2005-0843

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  30 in total

1.  Education and employment status of children and adults with thalassemia in North America.

Authors:  Zahra Pakbaz; Marsha Treadwell; Hae-Young Kim; Felicia Trachtenberg; Nagina Parmar; Janet L Kwiatkowski; Melody J Cunningham; Marie Martin; Nancy Sweeters; Ellis J Neufeld; Patricia J Giardina; Nancy Olivieri; Robert C Yamashita; Elliott Vichinsky
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

2.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

3.  Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME).

Authors:  Elliott Vichinsky; Lynne Neumayr; Sean Trimble; Patricia J Giardina; Alan R Cohen; Thomas Coates; Jeanne Boudreaux; Ellis J Neufeld; Kristy Kenney; Althea Grant; Alexis A Thompson
Journal:  Transfusion       Date:  2013-07-25       Impact factor: 3.157

4.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

5.  Pediatric hematology providers on referral for transplant evaluation for sickle cell disease: a regional perspective.

Authors:  Bethany Mikles; Monica Bhatia; Suzette O Oyeku; Zhezhen Jin; Nancy S Green
Journal:  J Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.289

6.  Prenatal Screening for Rare Co-Inheritance of HbE and β-Thalassaemia Traits in Western India.

Authors:  Parth S Shah; Hari Shankar P Ray; Ketan K Vaghasia; Sandip C Shah; Mandava V Rao
Journal:  J Clin Diagn Res       Date:  2017-09-01

7.  Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover.

Authors:  Ellen B Fung; Elliott P Vichinsky; Janet L Kwiatkowski; James Huang; Laura K Bachrach; Aenor J Sawyer; Babette S Zemel
Journal:  Bone       Date:  2011-04-05       Impact factor: 4.398

8.  Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer.

Authors:  Giuseppe Verlato; Simone Giacopuzzi; Maria Bencivenga; Paolo Morgagni; Giovanni De Manzoni
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

9.  Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia.

Authors:  Guanheng Yang; Wansheng Shi; Xingyin Hu; Jingzhi Zhang; Zhijuan Gong; Xinbing Guo; Zhaorui Ren; Fanyi Zeng
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

10.  Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children.

Authors:  Arthorn Riewpaiboon; Issarang Nuchprayoon; Kitti Torcharus; Kaemthong Indaratna; Montarat Thavorncharoensap; Bang-On Ubol
Journal:  BMC Res Notes       Date:  2010-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.